Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of CBP-307 in Healthy Subjects
NCT02280434Phase 1Completed
- Sponsor
- Connect Biopharma
- Start
- Nov 2014
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune diseases comparing CBP-307 with Placebo (2 arms). Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability up to 6 weeks. Started Nov 2014; status: completed.
02
Drugs
icanbelimod
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT02280434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02280434.